Tolebrutinib is currently in clinical development for the treatment of relapsing forms of multiple sclerosis (RMS). MS is a chronic autoimmune condition that affects the brain and spinal cord, it can lead to increased mortality and is one of the most common causes of disability in younger adults as it is most diagnosed in people in their 20s, 30s and 40s. RMS is the most common form of MS and is characterised by episodes of acute worsening of function followed by partial or complete recovery. Common symptoms in RMS around the time of diagnosis are problems with eyesight, slowed thinking (cognitive symptoms), unusual feelings in the skin (such as pins and needles or numbness) and fatigue.
Tolebrutinib for treating relapsing multiple sclerosis
Tolebrutinib is currently in clinical development for the treatment of relapsing forms of multiple sclerosis (RMS). MS is a chronic autoimmune condition that affects the brain and spinal cord, it can lead to increased mortality and is one of the most common causes of disability in younger adults as it is most diagnosed in people in their 20s, 30s and 40s.
Interventions:
Tolebrutinib (PRN-2246;SAR-442168)
Indications:
Multiple sclerosis (MS)
Therapeutic Areas:
Neurology
Year:
2023